San Mateo, United States
Helicore Biopharma, founded in 2025, is a rapidly emerging player in the Biotechnology and Pharmaceutical sectors. With its compelling slogan, "Long-Acting Medicines to Transform Metabolic Health," the company is innovatively addressing obesity and cardiometabolic disease through its proprietary antibody-peptide conjugate platform.
The company has successfully developed proprietary libraries of GLP-1R agonist and amylin receptor agonist therapeutic peptides. These are optimized for bias, selectivity, and potency, ensuring stability and durability when conjugated with therapeutic antibodies. The hallmark of Helicore's pipeline is the proprietary GIP ligand binder antibody, which has shown exceptional safety and target engagement in Phase 1 trials.
Helicore's recent $65.00M Series A funding on January 1, 2025, led by investors like Longitude Capital, OrbiMed, Versant Ventures, and Wellington Management, positions it well for scaling and innovation. The team’s robust experience in metabolic disease underscores their potential for significant market impact.
